Glaucoma
Understanding Glaucoma
Glaucoma is a group of eye diseases that damage the optic nerve, leading to vision loss and, if untreated, blindness. In most cases, this damage is linked to elevated intraocular pressure (IOP) caused by improper drainage of the eye’s fluid. As fluid builds up, the pressure increases, gradually harming the optic nerve.
Globally, over 76 million people are affected by glaucoma, a number expected to surpass 110 million by 2040. In India, glaucoma accounts for 12.8% of blindness, with more than 3 million people worldwide already blind due to the disease.
Challenges in Early Detection
Glaucoma is often called the “silent blinder” because it progresses without noticeable symptoms until significant damage has occurred. Early signs, such as peripheral vision loss, frequently go undetected, and without timely intervention, the disease can lead to complete blindness.
Diagnosing glaucoma typically requires multiple tests, including tonometry, OCT imaging, and visual field testing. However, access to these tests and patient adherence to regular screenings remain significant barriers—especially since early symptoms are rarely apparent.
Challenges in Early Detection
Glaucoma is often called the “silent blinder” because it progresses without noticeable symptoms until significant damage has occurred. Early signs, such as peripheral vision loss, frequently go undetected, and without timely intervention, the disease can lead to complete blindness.
Diagnosing glaucoma typically requires multiple tests, including tonometry, OCT imaging, and visual field testing. However, access to these tests and patient adherence to regular screenings remain significant barriers—especially since early symptoms are rarely apparent.
Advancing Glaucoma Detection with FH-POISE
FH-POISE transforms glaucoma detection by combining cutting-edge imaging technology with advanced analysis to deliver precise, automated insights.
How FH-POISE Works:
Integrated Insights
Analyzes key diagnostic parameters, including cup-to-disc ratio (CDR) and ISNT values, to detect early signs of glaucoma.
Comprehensive Reports
Provides detailed, AI-generated assessments that support clinicians in making data-driven decisions.
Enhanced Clinical Workflow
Streamlines the diagnostic process, enabling earlier intervention and improving patient outcomes.
With its advanced capabilities, FH-POISE ensures timely detection of glaucoma, optimized clinical workflows, and better patient care.
References and External Links
- Eye Conditions and Diseases Glaucoma
https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/glaucoma - Eye Health Glaucoma
https://www.webmd.com/eye-health/glaucoma-eyes - Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis
https://pubmed.ncbi.nlm.nih.gov/24974815/ - Prevalence of glaucoma types, clinical profile and disease severity at presentation: Tertiary Institute based cross-sectional study from South India
https://journals.lww.com/ijo/fulltext/2023/71100/prevalence_of_glaucoma_types,_clinical_profile_and.8.aspx - conditions and diseases glaucoma
https://www.hopkinsmedicine.org/health/conditions-and-diseases/glaucoma - Diseases & Conditions Glaucoma
https://my.clevelandclinic.org/health/diseases/4212-glaucoma?sm_guid=MTQ4NTAxfDExNjE0NjM5fC0xfGFubmZvbmZhQGFvbC5jb218ODcxMjMxfHwwfDB8MzM5MDE5NjV8ODM3fDB8MHw1
